Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.National Jewish Health (NJH) has received $12.7m counteract grant award from National Institutes of Health (NIH) to continue development of AEOL 10150 for treating chlorine and sulfur mustard gas exposure.
Subscribe to our email newsletter
The contract also supports the research on plasminogen activator (TPA) and Silabilin as MCM’s against sulfur mustard gas exposure.
AEOL can also be used to treat pulmonary injuries resulting from exposure to radiation.
NJH intends to run efficacy studies in the rat model for higher doses of sulfur mustard and chlorine gas besides establishing endpoints, optimal dosing and duration of treatment for pivotal efficacy studies.
The earlier work that has demonstrated the efficacy of AEOL in protecting the lungs from damage due to inhalation of chlorine gas and sulfur mustard gas will support the new study.